How rare is AL amyloidosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

How Rare is AL Amyloidosis?

AL amyloidosis is a rare disease with an estimated incidence of approximately 9.7–14.0 cases per million person-years in the United States, translating to at least 12,000–45,000 adults currently living with the condition. 1, 2

Incidence and Prevalence Data

United States Epidemiology

  • Incidence: Approximately 12 cases per million persons per year, with claims-based studies showing a range of 9.7–14.0 cases per million person-years between 2007–2015 1, 2
  • Prevalence: Increased significantly from 15.5 cases per million in 2007 to 40.5 cases per million in 2015, representing an annual percentage change of 12% 1
  • The rising prevalence coupled with stable incidence suggests improved survival and earlier detection, with current estimates of 30,000–45,000 cases in the US and European Union combined 2

Comparative Rarity

  • AL amyloidosis affects fewer than 200,000 people in the United States, officially classifying it as a rare disease according to the National Institutes of Health 3
  • For context, AL amyloidosis is substantially more common than variant ATTR amyloidosis (0.3 cases per million per year) but less common than wild-type ATTR amyloidosis (prevalence of 155–191 cases per million) 2

Clinical Implications of Rarity

Diagnostic Challenges

  • The rarity of AL amyloidosis contributes to delayed diagnosis, as symptoms mimic other more common conditions 4
  • Many patients are diagnosed only after disease progression to advanced stages with irreversible organ damage 4, 5
  • The paucity of literature and clinical awareness poses additional constraints in recognizing this condition 4

Systemic Nature at Presentation

  • More than 69% of patients present with multiple organ involvement at diagnosis, with a median of 2 affected sites 6, 4
  • The heart and kidneys are most commonly affected, though any organ except the central nervous system can be involved 4, 7
  • Cardiac involvement is the principal determinant of prognosis and mortality 6

Mortality Context

The rarity of AL amyloidosis belies its lethality:

  • 25% of patients die within 6 months of diagnosis 2
  • Without treatment, median survival varies dramatically by cardiac staging, from 82% 5-year survival in Stage I to 34% in Stage III 6
  • Early diagnosis and rapid therapeutic intervention are critical to prevent irreversible organ damage 6

References

3
Research

The amyloidoses: clinical features, diagnosis and treatment.

Methodist DeBakey cardiovascular journal, 2012

6
Guideline

First‑Line Treatment Recommendations for AL Amyloidosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What are the red flag signs and symptoms that should prompt evaluation for amyloidosis?
What are the treatment options for systemic amyloidosis?
Can pancytopenia occur in amyloidosis?
What is the timeframe for amyloid buildup in organs?
In a 71‑year‑old woman with a very high atypical P‑ANCA (perinuclear anti‑neutrophil cytoplasmic antibodies) titer, markedly elevated free κ and λ light chains, increased γ‑globulin and total globulin, what is the likely diagnosis and what diagnostic work‑up and initial treatment should be pursued?
For a patient on dual antiplatelet therapy (DAPT), which proton‑pump inhibitor (PPI) should be prescribed?
What are the differences between early‑onset (before 34 weeks) and late‑onset (≥34 weeks) pre‑eclampsia regarding management, delivery timing, and long‑term maternal health implications?
What are the blood loss–related side effects of Eliquis (apixaban)?
What is the appropriate workup for a patient with normal prolactin, normal follicle‑stimulating hormone, normal luteinizing hormone, and low estradiol?
Can heart failure present with hematuria?
Can you provide comprehensive information on transposition blepharoplasty, including its indications, pre‑operative assessment, surgical technique, postoperative care, potential complications, and alternative procedures?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.